Nothing Special   »   [go: up one dir, main page]

van Rossum et al., 2010 - Google Patents

Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives

van Rossum et al., 2010

View PDF
Document ID
11177094627640072166
Author
van Rossum H
de Fijter J
van Pelt J
Publication year
Publication venue
Therapeutic drug monitoring

External Links

Snippet

The calcineurin inhibitors (CNIs) cyclosporin A and tacrolimus are immunosuppressive drugs used extensively in allograft recipients. These drugs show large interindividual pharmacokinetic variation and are associated with severe adverse affects, including …
Continue reading at scholarlypublications.universiteitleiden.nl (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay

Similar Documents

Publication Publication Date Title
van Rossum et al. Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives
Boleslawski et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection
Knight et al. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review
Shipkova et al. Surface markers of lymphocyte activation and markers of cell proliferation
Wieland et al. Biomarkers as a tool for management of immunosuppression in transplant patients
Gummert et al. Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics
Langman et al. Pharmacodynamic assessment of mycophenolic acidinduced immunosuppression in renal transplant recipients
Millán et al. Intracellular IFN-γ and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients
van Gelder et al. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation
Millan et al. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil
Decouture et al. Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice
Sommerer et al. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression
Chau et al. HuM291 (NUVION), A HUMANIZED Fc RECEPTOR-NONBINDING ANTIBODY AGAINST CD3, ANERGIZES PERIPHERAL BLOOD T CELLS AS PARTIAL AGONIST OF THE T CELL RECEPTOR1
Casiraghi et al. Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction
Caruso et al. Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients
Sommerer et al. Pharmacodynamic monitoring of calcineurin inhibitor therapy: Is there a clinical benefit?
Barten et al. Assessment of immunosuppressive drug interactions: inhibition of lymphocyte function in peripheral human blood
Vafadari et al. Inhibitory effect of tacrolimus on p38 mitogen-activated protein kinase signaling in kidney transplant recipients measured by whole-blood phosphospecific flow cytometry
Boleslawski et al. CD25, CD28 and CD38 expression in peripheral blood lymphocytes as a tool to predict acute rejection after liver transplantation
Sommerer et al. Nuclear Factor of Activated T Cells–Regulated Gene Expression as Predictive Biomarker of Personal Response to Calcineurin Inhibitors
Nikolaeva et al. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells
Albring et al. Relationship between pharmacokinetics and pharmacodynamics of calcineurin inhibitors in renal transplant patients
Vafadari et al. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients
Bremer et al. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression
Matsuda et al. Immunosuppressants decrease neutrophil chemoattractant and attenuate ischemia/reperfusion injury of the liver in rats